Luminex Corp. (NASDAQ:LMNX) has been given an average rating of “Hold” by the seven ratings firms that are presently covering the company. Six investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.80.

A number of research analysts have recently commented on the company. William Blair reissued a “market perform” rating on shares of Luminex Corp. in a report on Tuesday, November 1st. Avondale Partners began coverage on Luminex Corp. in a report on Wednesday, October 12th. They issued an “outperform” rating and a $27.00 target price on the stock. JPMorgan Chase & Co. raised Luminex Corp. from an “underweight” rating to a “neutral” rating and raised their target price for the company from $18.00 to $22.00 in a report on Thursday, August 18th. Jefferies Group raised their target price on Luminex Corp. from $21.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 28th. Finally, Zacks Investment Research lowered Luminex Corp. from a “buy” rating to a “hold” rating in a report on Thursday, July 28th.

Luminex Corp. (NASDAQ:LMNX) opened at 20.50 on Friday. Luminex Corp. has a 52 week low of $17.29 and a 52 week high of $23.75. The company has a market capitalization of $893.47 million, a P/E ratio of 23.64 and a beta of 0.57. The company’s 50-day moving average price is $21.17 and its 200-day moving average price is $21.15.

Luminex Corp. (NASDAQ:LMNX) last issued its quarterly earnings data on Monday, October 31st. The company reported $0.21 EPS for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.09. The business had revenue of $71.20 million for the quarter, compared to analyst estimates of $68.90 million. Luminex Corp. had a return on equity of 11.95% and a net margin of 14.51%. The firm’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.22 EPS. On average, equities analysts forecast that Luminex Corp. will post $0.52 EPS for the current fiscal year.

In other Luminex Corp. news, Director Kevin M. Mcnamara sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The stock was sold at an average price of $21.03, for a total value of $252,360.00. Following the completion of the sale, the director now owns 67,274 shares in the company, valued at approximately $1,414,772.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Harriss T. Currie acquired 4,100 shares of Luminex Corp. stock in a transaction on Thursday, November 3rd. The stock was purchased at an average price of $18.20 per share, with a total value of $74,620.00. The disclosure for this purchase can be found here. 6.90% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. ClariVest Asset Management LLC increased its stake in shares of Luminex Corp. by 33,173.3% in the third quarter. ClariVest Asset Management LLC now owns 4,991 shares of the company’s stock worth $113,000 after buying an additional 4,976 shares in the last quarter. Victory Capital Management Inc. increased its position in Luminex Corp. by 37.7% in the third quarter. Victory Capital Management Inc. now owns 5,120 shares of the company’s stock valued at $116,000 after buying an additional 1,401 shares during the period. Teacher Retirement System of Texas increased its position in Luminex Corp. by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 5,429 shares of the company’s stock valued at $110,000 after buying an additional 659 shares during the period. SG Americas Securities LLC bought a new position in Luminex Corp. during the third quarter valued at approximately $143,000. Finally, Mason Street Advisors LLC bought a new position in Luminex Corp. during the second quarter valued at approximately $153,000. Institutional investors own 79.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Luminex Corp. (LMNX) Receives Average Rating of “Hold” from Analysts” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of United States & international copyright laws. The original version of this article can be accessed at

Luminex Corp. Company Profile

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

5 Day Chart for NASDAQ:LMNX

Receive News & Stock Ratings for Luminex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Corp. and related stocks with our FREE daily email newsletter.